The latest price target for Fulcrum Therapeutics (NASDAQ:FULC) was reported by HC Wainwright & Co. on February 26, 2025. The analyst firm set a price target for $4.00 expecting FULC to rise to within 12 months (a possible 26.58% upside). 18 analyst firms have reported ratings in the last year.

The latest analyst rating for Fulcrum Therapeutics (NASDAQ:FULC) was provided by HC Wainwright & Co., and Fulcrum Therapeutics reiterated their neutral rating.

The last upgrade for Fulcrum Therapeutics Inc happened on September 9, 2024 when B of A Securities raised their price target to $10. B of A Securities previously had an underperform for Fulcrum Therapeutics Inc.

The last downgrade for Fulcrum Therapeutics Inc happened on September 13, 2024 when RBC Capital changed their price target from $15 to $4 for Fulcrum Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Fulcrum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Fulcrum Therapeutics was filed on February 26, 2025 so you should expect the next rating to be made available sometime around February 26, 2026.

While ratings are subjective and will change, the latest Fulcrum Therapeutics (FULC) rating was a reiterated with a price target of $4.00 to $4.00. The current price Fulcrum Therapeutics (FULC) is trading at is $3.16, which is out of the analyst’s predicted range.